As site Principle Investigator for the Centre for International Bone Marrow Transplant Research (CIBMTR) group, my interests are focused on co-operative, inter-disciplinary programmes aimed at tackling the varied challenges presented by pediatric oncology and hematology patients.

My background in engineering and current experience as a U.S. Naval Flight Surgeon underlines my interest in human factor analysis and risk management within the practice of medicine. In an effort to reduce risk in health management to its lowest possible level, the naval aviation community's use of the "best practice" process to effectively identify, analyze and eliminate or help control a hazard can successfully be applied to our daily endeavors in medicine and will provide insight and options to our practices.


Successful clinical treatment and functional immunological normalization of human MALT1 deficiency following hematopoietic stem cell transplantation
Clinical Immunology
Jacob Rozmus, Rachel McDonald, Shan-Yu Fung, Kate L. Del Bel, Juliana Roden, Christof Senger, Kirk R. Schultz, Margaret L. McKinnon, Jeffrey Davis, Stuart E. Turvey
DOI: 10.1016/j.clim.2016.04.011

Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin
Biology of Blood and Marrow Transplantation
Alok Kothari, Alexander Ngwube, Robert Hayashi, Lisa Murray, Jeffrey Davis, Paul Haut, Brett J. Loechelt, Shalini Shenoy
DOI: 10.1016/j.bbmt.2015.03.019

Optimizing outcomes of hematopoietic stem cell transplantation for severe combined immunodeficiency
Clinical Immunology
Geoff D.E. Cuvelier, Kirk R. Schultz, Jeff Davis, Aaron F. Hirschfeld, Anne K. Junker, Rusung Tan, Stuart E. Turvey
DOI: 10.1016/j.clim.2009.01.003

Torticollis as a sign of cervico-thoracic epidural haematoma in an infant with severe haemophilia A
DOI: 10.1111/j.1365-2516.2006.01323.x

Detection of a novel nonsense mutation in the interleukin 2 receptor gamma gene causing X-linked severe combined immunodeficiency
Annals of Allergy, Asthma & Immunology
Lindsay Cohen and Aaron F. Hirschfeld and Anne K. Junker and Jeff Davis and Stuart E. Turvey
DOI: 10.1016/s1081-1206(10)63563-6

Improving patient safety by design — a new spinal/intrathecal injection safety system
Canadian Journal of Anesthesia/Journal canadien d'anesthésie
Ian Sheppard, Jeff Davis, Derek Blackstock
DOI: 10.1007/bf03021540

Identification and functional characterization of 2 variant alleles of the telomerase RNA template gene (TERC) in a patient with dyskeratosis congenita
H. Ly
DOI: 10.1182/blood-2005-01-0247

Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis
Bone Marrow Transplantation
D L Forrest, T J Nevill, S C Naiman, A Le, D A Brockington, M J Barnett, J C Lavoie, S H Nantel, K W Song, J D Shepherd, H J Sutherland, C L Toze, J H Davis, D E Hogge
DOI: 10.1038/sj.bmt.1704243

Non-resectable congenital tumors with theETV6-NTRK3 gene fusion are highly responsive to chemotherapy
Medical and Pediatric Oncology
Emma McCahon, Poul H.B. Sorensen, Jeff H. Davis, Paul C.J. Rogers, Kirk R. Schultz
DOI: 10.1002/mpo.10272

Candida dubliniensis Fungemia and Vascular Access Infection
Journal of Pediatric Hematology/Oncology
Nevio Cimolai, Jeff Davis, Colleen Trombley
DOI: 10.1097/00043426-200203000-00017

High-Dose Melphalan, Etoposide, Total-Body Irradiation, and Autologous Stem-Cell Reconstitution as Consolidation Therapy for High-Risk Ewing’s Sarcoma Does Not Improve Prognosis
Journal of Clinical Oncology
Paul A. Meyers, Mark D. Krailo, Marc Ladanyi, Ka-Wah Chan, Scott L. Sailer, Paul S. Dickman, David L. Baker, Jeffrey H. Davis, Robert B. Gerbing, Alfred Grovas, Cynthia E. Herzog, Karen L. Lindsley, Wen Liu-Mares, James B. Nachman, Lance Sieger, Jean Wadman, Richard G. Gorlick
DOI: 10.1200/jco.2001.19.11.2812

Diamond-Blackfan Anemia and Cyclosporine Therapy Revisited
Journal of Pediatric Hematology/Oncology
Angela J. Alessandri, Paul C. Rogers, Louis D. Wadsworth, Jeffrey H. Davis
DOI: 10.1097/00043426-200003000-00020

Successful use of cyclosporine A in the treatment of refractory thrombotic thrombocytopenic purpura
British Journal of Haematology
Hand, Lawlor, Yong, Davis
DOI: 10.1046/j.1365-2141.1998.00602.x

Immunosuppressive Therapy: A Potential Alternative to Bone Marrow Transplantation as Initial Therapy for Acquired Severe Aplastic Anemia in Childhood?
Journal of Pediatric Hematology/Oncology
Elizabeth R. Lawlor, Ronald A. Anderson, Jeffrey H. Davis, Christopher J. H. Fryer, Sheila L. Pritchard, Paul C. J. Rogers, John K. Wu, Kirk R. Schultz
DOI: 10.1097/00043426-199703000-00004

Erythropoietin therapy in neonates at risk of having bronchopulmonary dysplasia and requiring multiple transfusions
The Journal of Pediatrics
Turki Al-Kharfy, John A. Smyth, Louis Wadsworth, Gerald Krystal, Colleen Fitzgerald, Jeffrey Davis, Ruth Milner
DOI: 10.1016/s0022-3476(96)70194-4

Infantile choriocarcinoma. Re-examination of a potentially curable entity
Deborah A. Belchis, Jeanne Mowry, Jeffrey H. Davis
DOI: 10.1002/1097-0142(19930915)72:63.0.co;2-g

Treatment of Malignancy with Unmodified Antibody
Pathology and Immunopathology Research
Christopher C. Badger, Claudio Anasetti, Jeff Davis, Irwin D. Bernstein
DOI: 10.1159/000157067


A study of hematopoietic stem cell transplantation (HSCT) in non-malignant disease using a reduced-intensity preparatory regime with campath-H, fludarabine and malphalan
It is hoped that this study will provide evidence that a preparative regimen consisting of a combination of campath-H, fludarabine and malphalan will maximize host immunosuppression without myeloablation, while being well tolerated and sufficient for engraftment of donor hemopoietic cells when minimally mismatched from the recipient or acquired from unrelated sources. It is postulated that this combination will allow for the gradual transition from recipient chimerism to full donor chimerism with minimal early and delayed toxicity to the recipient. The target is children with non-malignant diseases who are benefited by transplantation and for whom myeloablation is not necessary.

Demonstration of human safety & physician acceptance of a unique spinal injection safety system (SISS)
The inadvertent administration of the wrong drug, by the spinal or epidural route, often with catastrophic results, continues to occur in medical practice. Several Canadian and world reports have demonstrated the tragic consequences in all medical fields utilizing spinal therapies, including oncology, anaesthesiology, and obstetrics. Specific recent cases of death as a result of the maladministration of vinca alkaloids into the spine have been reported widely. We have redesigned the spinal needle and system around intrathecal administration of medications and in this study we propose to implement the spinal injection safety system (SISS) in clinical practice. Through evaluating the SISS we will determine its safety attributes for pediatric patients receiving spinal chemotherapy and whether or not it meets the practice expectations of physicians. We also seek to significantly reduce the net risk of patient harm through inadvertent human error during the spinal drug administration procedure as well as be cost-effective in comparison to current practices.

Honours & Awards

Bruce W Jackson Memorial Award for the Reserve Flight Surgeon of the Year, The Society of United States Naval Flight Surgeons - 2014

Rookie of the Year Attending Award, University of British Columbia Residents - 1992